Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL)

CAPS Rating: 5 out of 5

The Company is a clinical-stage drug development company that discovers and develops novel, small molecule drugs for the treatment of inflammatory diseases, cancer and viral diseases.

Results 1 - 20 of 25 : 1 2 Next »

Recs

0
Member Avatar TTime0917 (< 20) Submitted: 6/20/2014 6:12:25 AM : Outperform Start Price: $4.05 RIGL Score: -49.76

Should have some very good recovery income in next two to three years

Recs

0
Member Avatar SqwiiTrader (< 20) Submitted: 4/30/2014 3:29:37 AM : Outperform Start Price: $3.46 RIGL Score: -39.94

IHS pattern monthly

Recs

0
Member Avatar sidiling (97.47) Submitted: 8/26/2013 10:32:36 AM : Outperform Start Price: $3.27 RIGL Score: -55.19

cash > mkt cap

Recs

0
Member Avatar AnsgarJohn (99.00) Submitted: 5/31/2013 5:39:36 AM : Outperform Start Price: $4.64 RIGL Score: -74.42

zzlangerhans (99.77) Submitted: 4/5/2013 7:20:40 PM : Start Price: $4.90 RIGL Score: -11.81
The street responded to news of mixed results of the OSKIRA-1 phase III trial of fostamatinib this morning as though the trial was an unequivocal failure. In fact, the trial failed to show improvement over placebo in RA by radiographic criteria but did show stat sig improvement by clinical criteria. If this type of outcome holds through subsequent trials the company and partner AstraZeneca may submit an NDA on the basis that clinical improvement trumps radiographic improvement.

As of the end of 2012, Rigel has about 300M in liquid assets to support a market cap of 392M at today's close. That's a reasonable bet for a rebound, although my personal preference would have been to let the stock get beaten up further when OSKIRA-2 and OSKIRA-3 results are released later this quarter, and then hopefully mop up closer to cash. In this case, my green thumb serves to support my real buy of 2000 shares this AM at 4.91 for the Portefeuille collaboration.

Recs

4
Member Avatar zzlangerhans (99.84) Submitted: 4/5/2013 7:20:40 PM : Outperform Start Price: $4.90 RIGL Score: -85.20

The street responded to news of mixed results of the OSKIRA-1 phase III trial of fostamatinib this morning as though the trial was an unequivocal failure. In fact, the trial failed to show improvement over placebo in RA by radiographic criteria but did show stat sig improvement by clinical criteria. If this type of outcome holds through subsequent trials the company and partner AstraZeneca may submit an NDA on the basis that clinical improvement trumps radiographic improvement.

As of the end of 2012, Rigel has about 300M in liquid assets to support a market cap of 392M at today's close. That's a reasonable bet for a rebound, although my personal preference would have been to let the stock get beaten up further when OSKIRA-2 and OSKIRA-3 results are released later this quarter, and then hopefully mop up closer to cash. In this case, my green thumb serves to support my real buy of 2000 shares this AM at 4.91 for the Portefeuille collaboration.

Recs

2
Member Avatar Momentum21 (81.79) Submitted: 4/5/2013 2:41:22 PM : Outperform Start Price: $4.90 RIGL Score: -85.28

Obviously this puts them in a tough spot with Fostamatinib but they do have a few bullets left to fire in 2013 along with some cash that was raised at the end of 2012. I think the offering priced at 9.50.

Not saying I have much of a valuation model on this decision going forward but i do like entry on a 37% decline when investors are panicking a bit in the broader market.

Bought at 4.79. Idea initiated by zzlangerhans and Portefeuille. It was on my watch list for several months and seems to be a fairly legit outfit with time on their side. Did I get a break on late entry or am I just throwing money into a rabbit hole? Time will decide. Wish me luck...

Recs

0
Member Avatar valuefocusgroup (20.93) Submitted: 4/4/2011 11:38:08 PM : Outperform Start Price: $7.20 RIGL Score: -118.35

Price/earnings of 10.04, Price/book of 2.26, Debt/equity ratio of zero, Return on Invested Capital (TTM) of 27.19, clinical-stage drug development company based in California, United States.

Recs

0
Member Avatar LuckyShad (65.42) Submitted: 3/14/2011 9:06:57 PM : Outperform Start Price: $6.70 RIGL Score: -123.68

There were 30 items in your list. Here they are in random order:

OSK CAPS=3 star
IPXL
PWER CAPS=4 star
VPHM
RIGL CAPS=2 star
SCEI
TSRA
DELL
POZN
MSFT
AFAM
APOL
VECO
AMED
VNDA
TNAV
ARO
SUPG
TER
SOLR
CMTL
UIS
PRSC
CHKE
SNDK
AGX
IDCC
LO
USMO
FRX
Timestamp: 2011-03-15 01:01:50 UTC

Recs

1
Member Avatar TMFBreakerJava (99.47) Submitted: 9/3/2009 11:56:28 PM : Outperform Start Price: $6.81 RIGL Score: -164.25

This company has a potential blockbuster in its pipeline, an orally available drug for rheumatoid arthritis. One phase II trial met its endpoint and then the stock was pummeled when a second trial failed to do so. The unusual circumstance was that the results in the drug arm of the second trial were just as good as those in the first, but the placebo arm did unexpectedly well. Trials are continuing and i believe that the drug will ultimately prove to be effective. There will be huge gains once that data is in.

Recs

0
Member Avatar tixlong (56.71) Submitted: 5/27/2009 5:10:48 PM : Outperform Start Price: $8.60 RIGL Score: -193.83

double dip

Recs

0
Member Avatar alicat2008 (94.74) Submitted: 11/11/2008 6:34:36 PM : Outperform Start Price: $7.12 RIGL Score: -197.95

cheap cheap cheap... let's see how it goes

Recs

1
Member Avatar AhWu (< 20) Submitted: 11/10/2008 10:48:51 AM : Outperform Start Price: $7.66 RIGL Score: -186.34

Stock has been unfairly punished over a slightly worrisome side effect in data from their their clinical trials for their oral Rheumatoid arthritis drug -- patients experienced increases in blood pressure, but those increases were manageable. It could prove a barrier to securing FDA approval, but based on the data available so far, it seems unlikely. Generally, the increase was too insignificant to be worrisome, and when doctors did decide to try to control the increase, they were able to easily do so with conventional blood pressure drugs.

All in all, it looks like a serious overreaction. and if that is the case, this stock represents a huge growth opportunity. After all, when they first released data about positive results of the same drug in the beginning of this year, the stock exploded 200% upwards. Now, since this latest information came out in October, ALL of those gains have been eroded. If Rigel can negotiate a partnership deal and the drug is approved, this stock will become a multi-bagger.

However, if larger, longer clinical trials bring to light any new safety issues, or indicate that known safety issues are more serious than they currently appear, than who knows where the bottom is. Don't put all your eggs in one basket, but in a diversified portfolio, this egg could become one hell of a chicken.

By the way, all of that information comes directly from this in-depth, thorough analysis:
http://seekingalpha.com/article/105033-rigel-pharmaceuticals-biotech-crisis-or-opportunity?source

Recs

0
Member Avatar tenmiles (99.67) Submitted: 10/28/2008 9:52:36 AM : Outperform Start Price: $7.11 RIGL Score: -199.85

Believe sell-off related to arthritis drug is overdone at these levels - roughly two thirds of market cap now in cash - long dated, relatively "cheap" call option from current $7.49

Recs

0
Member Avatar Azulene (61.15) Submitted: 10/13/2008 6:43:28 AM : Outperform Start Price: $18.26 RIGL Score: -200.10

Drugs in pipeline

Recs

2
Member Avatar imaphule2 (97.83) Submitted: 6/27/2008 4:05:43 PM : Outperform Start Price: $23.25 RIGL Score: -148.16

Buyout candidate in a major way. Why? NHL drug showed 60% effectiveness in PII trial - yes it was small but that is so statistically significant it is unlikely to go away completely. Assuming 8,000 new potential patients per year we have a drug that will bring in 500M at its peak, maybe more (depends on additional applications). Soooo... why a buyout? The cost of bringing a drug to market is approx 1.2B. They don't have that kind of $. More importantly, given the cost of getting a FDA approved manufacturing facility up and running is also a B. Should the get approval and not at least partner it they will be a victim of their own success. They (probably) know this. They need a company with deep pockets to fund their clinical trial for NHL as well as the rest of their (for their size) respectable pipeline. Looking at past deals for similar companies in this situation I would estimate the buyout at 2-3B. The only real questions are when and who.

Recs

1
Member Avatar ScreenerStizBear (83.59) Submitted: 6/26/2008 2:26:22 PM : Underperform Start Price: $22.85 RIGL Score: +146.68

I simply used the screener to identify 1-star companies with the highest 52-week gain. The 1-star rating should mean they are bad companies and the 52-week gain should mean they are overpriced. We’ll see how it works!

Recs

1
Member Avatar deuspecuniae (96.26) Submitted: 5/1/2008 12:11:16 PM : Outperform Start Price: $22.77 RIGL Score: -135.59

The looming recession that bernanke and the whole federal reserve gang have set this country towards will send alot of investors into the pharmaceutical's sector--being the traditional recessionary savior to say the least. Plus, most pharmaceutical stocks have been beaten down this past winter, and I see a reversal across the entire sector. Also, those companies already on a run will continue due to the upward momentum this summer from key reversals and upgrades throughout the sector.

Recs

1
Member Avatar ddebo44 (49.90) Submitted: 4/24/2008 10:20:09 PM : Outperform Start Price: $21.35 RIGL Score: -135.17

This drug development company has several products in the pipeline and agreements with the major industry players.

Recs

1
Member Avatar yakky (28.25) Submitted: 2/21/2008 3:26:00 PM : Outperform Start Price: $19.60 RIGL Score: -140.22

Temporarily down, rising back soon

Recs

0
Member Avatar menelyik (< 20) Submitted: 12/14/2007 12:36:15 PM : Underperform Start Price: $27.91 RIGL Score: +130.38

mo mo money will soon get tired
of a drug that hasn't yet even been approved,
and will have plenty of competition when it arrives.
the run-up yesterday and today havs been way overdone.

Results 1 - 20 of 25 : 1 2 Next »

Featured Broker Partners


Advertisement